Physician profile
Debbie Ali
NPI 1669929204
$58,176.33
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $650 · 2020: $312 · 2021: $1,025 · 2022: $9,702 · 2023: $24K · 2024: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Travel and Lodging: $13K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $10K · Food and Beverage: $5,680 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,900.00 |
| Travel and Lodging | $12,589.04 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $10,300.00 |
| Food and Beverage | $5,680.05 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $50,457.28 | 2021-2024 | |
| Bausch & Lomb Americas INC. | $1,300.85 | 2022-2024 | Miebo, Xiidra, Infuse |
| Abbvie INC. | $1,251.75 | 2022-2024 | Lumigan, Vuity, Durysta |
| New World Medical,INC. | $697.80 | 2023-2024 | Ahmed Glaucoma Valve, Clearpath, Kahook Dual Blade |
| Sight Sciences, INC. | $517.88 | 2021-2024 | Omni Surgical System |
| Oyster Point Pharma, INC. | $468.83 | 2022-2024 | Tyrvaya, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $388.42 | 2019 | |
| Sun Pharmaceutical Industries INC. | $347.85 | 2021-2024 | Cequa |
| Aerie Pharmaceuticals, INC. | $316.84 | 2021 | |
| Novartis Pharmaceuticals Corporation | $300.31 | 2021-2023 | |
| Alcon Vision LLC | $285.71 | 2019-2024 | Rocklatan, Eysuvis, Hydrus Microstent |
| Johnson & Johnson Surgical Vision, INC. | $268.38 | 2021-2023 | Meibomian Gland Evaluator |
| Optos, INC. | $221.17 | 2020-2022 | |
| Allergan, INC. | $214.13 | 2021 | |
| Glaukos Corporation | $167.06 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $151.45 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $150.00 | 2023 | Balversa, Erleada, Abiraterone Acetate |
| Tarsus Pharmaceuticals, INC. | $136.08 | 2024 | Xdemvy |
| Maculogix, INC. | $129.36 | 2020 | |
| Topcon Healthcare, INC. | $121.96 | 2020 | |
| Eyevance Pharmaceuticals LLC | $95.96 | 2022 | |
| Kala Pharmaceuticals, INC. | $78.71 | 2021-2022 | |
| Dompe US, INC. | $56.60 | 2022-2024 | Oxervate |
| Mallinckrodt Hospital Products INC. | $33.31 | 2024 | Acthar |
| Janssen Biotech, INC. | $18.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debbie Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.